Case Statistics

Defendant Name: GlaxoSmithKline, Sanofi et al.
Case Number: 1:19-cv-0777
Court: U.S. District Court for the Northern District of Illinois
Practice Area: Consumer Fraud, Dangerous Drugs & Defective Products
Status: Active
Date Filed: 11/26/2019

Case Overview

FeganScott filed a national class action lawsuit on behalf of a nationwide class of consumers, claiming pharmaceutical giants GlaxoSmithKline and Sanofi, among others, failed to warn consumers that the heartburn medication, Zantac, produces a clinically proven carcinogen in the body at levels far beyond what regulators consider safe.

According to the suit, Zantac and its generic active ingredient, ranitidine, became one of the world’s best-selling drugs through a massive advertising campaign that touted the drug as safe. However, the complaint cites studies that ranitidine, when metabolized, creates N-nitrosodimethylamine (NDMA), which the EPA, FDA and World Health Organization (WHO) deem a carcinogen.

The lawsuit seeks to represent anyone who purchased Zantac or its generic equivalent, ranitidine, and asks the court to set up a medical monitoring program to diagnose and treat any related cancers and demands punitive damages for defendants’ outrageous and intentional conduct.